Condition: Heparin-induced Thrombocytopenia · Sponsor: University of Arizona
The purpose of this research is to identify genomic markers that can predict heparin-induced thrombocytopenia (HIT), which is a very serious side effect to heparin. Heparin is commonly used to prevent blood clots and the investigators may be able to identify genomic markers which can be used to prevent heparin use in people who will get HIT.
This description comes directly from the study's public registry record.
Jason H Karnes, PharmD, PhD · 520-626-1447 · karnes@pharmacy.arizona.edu
Talin A Robinson-Catalan, MS · 520-278-6114 · talinrobinson@arizona.edu
Always discuss trial participation with your own doctor first.
| Banner University Medical Center - Tucson | Tucson, Arizona, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02717039